236 related articles for article (PubMed ID: 28544973)
1. PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8
Sekiya T; Yamagishi J; Gray JHV; Whitney PG; Martinelli A; Zeng W; Wong CY; Sugimoto C; Jackson DC; Chua BY
Biomaterials; 2017 Aug; 137():61-72. PubMed ID: 28544973
[TBL] [Abstract][Full Text] [Related]
2. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
[TBL] [Abstract][Full Text] [Related]
3. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses.
Chua BY; Olson MR; Bedoui S; Sekiya T; Wong CY; Turner SJ; Jackson DC
Immunol Cell Biol; 2014 Apr; 92(4):377-83. PubMed ID: 24394993
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity.
Wijayadikusumah AR; Sullivan LC; Jackson DC; Chua BY
Amino Acids; 2017 Oct; 49(10):1691-1704. PubMed ID: 28718065
[TBL] [Abstract][Full Text] [Related]
5. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.
Chua BY; Pejoski D; Turner SJ; Zeng W; Jackson DC
J Immunol; 2011 Aug; 187(4):1692-701. PubMed ID: 21742967
[TBL] [Abstract][Full Text] [Related]
6. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
[TBL] [Abstract][Full Text] [Related]
7. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia.
Krishnaswamy JK; Jirmo AC; Baru AM; Ebensen T; Guzmán CA; Sparwasser T; Behrens GM
Am J Respir Cell Mol Biol; 2012 Dec; 47(6):852-63. PubMed ID: 22962064
[TBL] [Abstract][Full Text] [Related]
10. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
11. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
[TBL] [Abstract][Full Text] [Related]
13. Post-PEGylated and crosslinked polymeric ssRNA nanocomplexes as adjuvants targeting lymph nodes with increased cytolytic T cell inducing properties.
Lou B; De Beuckelaer A; Dakwar GR; Remaut K; Grooten J; Braeckmans K; De Geest BG; Mastrobattista E; De Koker S; Hennink WE
J Control Release; 2018 Aug; 284():73-83. PubMed ID: 29908893
[TBL] [Abstract][Full Text] [Related]
14. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
[TBL] [Abstract][Full Text] [Related]
15. Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.
Pitoiset F; Vazquez T; Levacher B; Nehar-Belaid D; Dérian N; Vigneron J; Klatzmann D; Bellier B
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794025
[TBL] [Abstract][Full Text] [Related]
16. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.
Chua BY; Johnson D; Tan A; Earnest-Silveira L; Sekiya T; Chin R; Torresi J; Jackson DC
PLoS One; 2012; 7(10):e47492. PubMed ID: 23091628
[TBL] [Abstract][Full Text] [Related]
18. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.
Tenbusch M; Nchinda G; Storcksdieck genannt Bonsmann M; Temchura V; Überla K
Int Immunol; 2013 Apr; 25(4):247-58. PubMed ID: 23184617
[TBL] [Abstract][Full Text] [Related]
19. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
20. Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.
Gutjahr A; Papagno L; Nicoli F; Lamoureux A; Vernejoul F; Lioux T; Gostick E; Price DA; Tiraby G; Perouzel E; Appay V; Verrier B; Paul S
J Immunol; 2017 Jun; 198(11):4205-4209. PubMed ID: 28432147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
